NCT04191499 2026-03-17
INAVO120
Hoffmann-La Roche
Phase 2/3 Active not recruiting
Clinical Trials
14 trialsNCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT07368998 2026-03-16
optINAVO
Hoffmann-La Roche
Phase 2 Recruiting
NCT03006172 2026-03-11
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Genentech, Inc.
Phase 1 Active not recruiting
NCT07405801 2026-03-09
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Hoffmann-La Roche
Phase 2 Recruiting
NCT06790693 2026-03-06
INAVO123
Hoffmann-La Roche
Phase 3 Recruiting
NCT05708235 2026-03-05
MiRaDoR
MedSIR
Phase 2 Recruiting
NCT07441512 2026-03-02
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT07347600 2026-02-20
reaINAVO
Hoffmann-La Roche
Recruiting
NCT05646862 2026-02-05
INAVO121
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT07245797 2025-11-24
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC
Fudan University
Phase 2 Not yet recruiting
NCT04849364 2025-05-31
PERSEVERE
Hoosier Cancer Research Network
Phase 2 Terminated
NCT05332561 2025-03-20
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
German Cancer Research Center
Phase 2 Recruiting
NCT05306041 2025-02-17
GeparPiPPa
GBG Forschungs GmbH
Phase 2 Recruiting